agena-bioscience-logo
  • Technology
  • Applications
  • Resources
  • Support
  • Company
  • Contact
EN - Global CN - 中国

menu

agena-bioscience-logo agena-bioscience-logo Close
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Liquid Biopsy
    • Mutation Profiling
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Mutation Profiling
    • Liquid Biopsy
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal

Phone: (858) 882-2800

Home / Resources / Publication Library

Search Results for: Mutation Profiling

Search All publications

How recent?
  • MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
  • Methylation epigenotypes and genetic features in colorectal laterally spreading tumors
  • Genetic Profiling to Determine Risk of Relapse Free Survival in High-risk Localized Prostate Cancer
  • ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer
  • Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment
  • Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas
  • Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers
  • BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma
  • Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
  • Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
«...102030...4647484950...»
Products
  • Technology
  • Applications
  • Custom Assays
Resources
  • Product Literature
  • Publication Library
  • ISO Certifications
  • Patents
    Support
    • Support Contacts
    • Service Plans
    • Certified Service Providers
    • Distributors
    • Customer Support Portal
Company
  • About Us
  • Careers
  • Contact
footer-logo
Agena Bioscience

4755 Eastgate Mall,
San Diego, CA 92121

(877) 443-6663

With exception of the MassARRAY Dx, all other products are For Research Use Only. Not for use in diagnostic procedures.
© 2020-2025 Agena Bioscience, Inc. All rights reserved. Agena Bioscience is a subsidiary of Mesa Labs, Inc.

  • footer-mesalabs-logo
  • footer-protein-logo
  • footer-gke-logo
  • Privacy Policy
  • Website Terms & Conditions
  • Product Terms & Conditions
  • Warranty